Lebrikizumab

FDA approves Eli Lilly's Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, targeting IL-13 cytokine. Supported by clinical trials showing 38% clear skin and 43% itch relief after 16 weeks, with 77% and 85% maintaining results after a year. Initially rejected in 2023 due to manufacturing concerns, approval follows EU and Japan approvals.

Eli Lilly’s Ebglyss (lebrikizumab) enters the U.S. atopic dermatitis market post FDA approval, competing with biologics like Dupixent and Adbry.

FDA approves Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and children 12+ years old, not well controlled by topical therapies. Ebglyss is a targeted IL-13 inhibitor addressing eczema inflammation.

FDA approves Eli Lilly’s Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and children aged 12+ weighing at least 88 lbs. Ebglyss targets the IL-13 pathway, with 38% achieving clear or almost-clear skin at 16 weeks vs. 12% on placebo. Common AEs include eye and eyelid inflammation, injection site reactions, and shingles.

FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis, offering once-monthly dosing. Ebglyss targets IL-13, providing clear skin in 38% of patients at 16 weeks, compared to 12% with placebo. Common side effects include eye inflammation, injection site reactions, and shingles.

FDA approves Eli Lilly's Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor for moderate-to-severe atopic dermatitis in adults and children 12+ years old who weigh at least 88 lbs and have uncontrolled eczema despite topical treatments. Ebglyss, a 250 mg/2 mL injection, can be used with or without topical corticosteroids, with an initial dose of 500 mg at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16, then monthly maintenance. Studies showed 38% achieved clear or almost clear skin at 16 weeks (vs. 12% placebo), with 77% maintaining results at one year.

FDA approves Eli Lilly's injectable eczema drug Ebglyss for adults and children 12+, targeting IL-13 protein. Available in weeks, it offers a monthly dosing option compared to competitors like Dupixent.

The FDA approved lebrikizumab (Ebglyss) for moderate to severe atopic dermatitis in patients aged 12+ weighing at least 88 lbs. This IL-13 inhibitor offers a new first-line biologic treatment, especially for those not well-controlled by topical therapies. It can be used with or without topical corticosteroids, with a recommended initial dose of 500 mg followed by 250 mg every 2 weeks until week 16, then monthly maintenance. Lebrikizumab is expected to be available in the US soon and has already been approved in Europe and Japan.